Recent advances in the development of NS5B polymerase inhibitors for the treatment of hepatitis C virus infection

Bibliography

• Choo QL, Kuo G, Weiner AJ, et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989;244:359-62
   PubMed Web of Science ®Google Scholar
• Lindenbach BD, Rice CM. Unravelling hepatitis C virus replication from genome to function. Nature 2005;436:933-8
   PubMed Web of Science ®Google Scholar
• Lohmann V, Körner F, Koch J, et al. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999;285:110-3
   PubMed Web of Science ®Google Scholar
• Wakita T, Pietschmann T, Kato T, et al. Production of infetious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005;11:791-6
   PubMed Web of Science ®Google Scholar
• Lamarre D, Anderson PC, Bailey M, et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 2003;426:186-9
   PubMed Web of Science ®Google Scholar
• Hinrichsen H, Benhamou Y, Wedemeyer H, et al. Short term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C virus genotype 1 patients. Gastroenterology 2004;127:1347-55
   PubMed Web of Science ®Google Scholar
• Meanwell NA, Koszalka GW. 2007: a difficult year for HCV drug development. Curr Opin Invest Drugs 2008;9:128-31
   PubMedGoogle Scholar
• Houghton M, Abrigani S. Prospects for a vaccine against the hepatitis C virus. Nature 2005;436:961-6
   PubMed Web of Science ®Google Scholar
• Foster G, Mathurin P. Hepatitis C virus therapy to date. Antivir Ther 2008;13(Suppl 1):3-8
   PubMed Web of Science ®Google Scholar
• Helle F, Dubuisson J. Hepatitis C virus entry into host cells. Cell Mol Life Sci 2008;65:100-12
   PubMed Web of Science ®Google Scholar
• Yang W, Zhao Y, Fabrycki J, et al. Selection of replicon variants resistant to ACH-806, a novel hepatitis C virus inhibitor with no cross-resistance to NS3 protease and NS5B polymerase inhibitors. Antimicrob Agents Chemother 2008;52:2043-52
   PubMed Web of Science ®Google Scholar
• Flisiak R, Dumont JM, Crabbé R. Cyclophilin inhibitors in hepatitis C viral infection. Expert Opin Investig Drugs 2007;16:1345-54
   PubMed Web of Science ®Google Scholar
• Dubuisson J, Helle F, Cocquerel L. Early steps of the hepatitis C virus life cycle. Cell Microbiol 2008;10:821-7
   PubMed Web of Science ®Google Scholar
• Huang Y, Staschke K, De Francesco R, et al. Phosphorylation of hepatitis C virus NS5A nonstructural protein: a new paradigm for phosphorylation-dependent viral RNA replication? Virology 2007;364:1-9
   PubMed Web of Science ®Google Scholar
• Koev G, Kati W. The emerging field of HCV drug resistance. Expert Opin Investig Drugs 2008;17:303-19
   PubMed Web of Science ®Google Scholar
• Beaulieu PL. Non-nucleoside inhibitors of the HCV NS5B polymerase: progress in the discovery and development of novel agents for the treatment of HCV infections. Curr Opin Investig drugs 2007;8:614-34
   PubMed Web of Science ®Google Scholar
• Koch U, Narjes F. Recent progress in the development of inhibitors of the hepatitis C virus RNA-dependent RNA polymerase. Curr Top Med Chem 2007;7:1302-29
   PubMed Web of Science ®Google Scholar
• De Francesco R, Carfi A. Advances in the development of new therapeutic agents targeting the NS3-4A serine protease or the NS5B RNA-dependent RNA polymerase of the hepatitis C virus. Adv Drug Deliv Rev 2007;59:1242-62
   PubMed Web of Science ®Google Scholar
• Beaulieu PL, Tsantrizos YS. Inhibitors of the HCV NS5B polymerase: new hope for the treatment of hepatitis C infection. Curr Opin Investig Drugs 2004;5:838-50
   PubMedGoogle Scholar
• Bressanelli S, Tomei L, Roussel A, et al. Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Proc Natl Acad Sci USA 1999;96:13034-9
   PubMed Web of Science ®Google Scholar
• Carroll SS, Olsen DB. Nucleoside analog inhibitors of hepatitis C virus replication. Inf Disord Drug Targets 2006;6:17-29
   PubMedGoogle Scholar
• Toniutto P, Fabris C, Bitetto D, et al. Valocipitabine dihydrochloride: a specific polymerase inhibitor of hepatitis C virus. Curr Opin Investig Drugs 2007;8:150-8
   PubMed Web of Science ®Google Scholar
• Carroll SS, Davies ME, Handt L, et al. Robust suppression of viral replication by a nucleoside polymerase inhibitor in chimpanzees infected with hepatitis C virus. Hepatology 2006;44(Suppl 1):535A
   Google Scholar
• Clarck JL, Hollecker L, Mason JC, et al. Design, synthesis and antiviral activity of 2′-deoxy-2′-fluoro-2′-C-methylcytidine, a potent inhibitor of hepatitis C virus replication. J Med Chem 2005;48:5504-5508
   PubMed Web of Science ®Google Scholar
• Murakami E, Bao H, Ramesh M, et al. Mechanism of activation of b-D-2′-deoxy-2′-fluoro-2′-C-methylcytidine and inhibition of hepatitis C virus NS5B RNA polymerase. Antimicrob Agents Chemother 2007;51:503-9
   PubMed Web of Science ®Google Scholar
• Ma H, Jiang WR, et al. Characterization of the metabolic activation of hepatitis C virus nucleoside inhibitor b-D-2′-deoxy-2′-fluoro-2′-C-methylcytidine (PSI-6130) and identification of a novel active 5'-triphosphate species. J Biol Chem 2007;282:29812-20
   PubMed Web of Science ®Google Scholar
• Murakami E, Niu C, Bao H, et al. The mechanism of action of b-D-2′-deoxy-2′-fluoro-2′-C-methylcytidine involves a second metabolic pathway leading to b-D-2′-deoxy-2′-fluoro-2′-C-methyluridine 5′-triphosphate, a potent inhibitor of the hepatitis C virus RNA-dependent RNA polymerase. Antimicrob Agents Chemother 2008;52:458-64
   PubMed Web of Science ®Google Scholar
• Lalezari J, Gane E, Rodriguez-Torres M, et al. Potent antiviral activity of the HCV nucleoside polymerase inhibitor R7128 with PEG-IFN and ribavirin: interim results of R7128 500 mg bid for 28 days [abstract 66]. Presented at the 43rd Annual Meeting of the European Association for the Study of the Liver; April 23 – 27 2008; Milan (Italy)
   Google Scholar
• Reddy R, Rodriguez-Torres M, Gane E, et al. Antiviral activity, pharmacokinetics, safety and tolerability of R7128, a novel nucleoside HCV RNA polymerase inhibitor, following multiple, ascending orale doses in patients with HCV genotype 1 infection who have failed prior interferon therapy [abstract LB9]. Presented at the 58th Annual Meeting of the American Association for the Study of Liver Disease; November 2 – 6 2007; Boston, MA
   Google Scholar
• Klumpp K, Lévêque V, Le Pogam S, et al. The novel nucleoside analog R1479 (4′-azidocytidine) is a potent inhibitor of NS5B-dependent RNA synthesis and hepatitis C virus replication in cell culture. J Biol Chem 2006;281:3793-9
   PubMed Web of Science ®Google Scholar
• Smith DB, Martin JA, Klumpp K, et al. Design, synthesis, and antiviral properties of 4′-substituted ribonucleoside as inhibitors of hepatitis C virus replication: the discovery of R1479. Bioorg Med Chem Lett 2007;17:2570-6
   PubMed Web of Science ®Google Scholar
• Pockros PJ, Nelson D, Godofsky E, et al. R1626 plus peginterferon alfa-2a provides potent suppression of hepatitis C virus RNA and significant synergy in combination with ribavirin. Hepatology 2008;48:385-97
   PubMed Web of Science ®Google Scholar
• Roberts KS, Cooksley G, Dore GJ, et al. Robust antiviral activity of R1626, a novel nucleoside analog: a randomized, placebo-controlled study in patients with chronic hepatitis C. Hepatology 2008;48:398-406
   PubMed Web of Science ®Google Scholar
• Hoffmann-La Roche Press Release, 21 October 2008
   Google Scholar
• McCown MF, Rajyaguru S, Le Pogam S, et al. The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors. Anti Microb Agents Chemother 2008;52:1604-12
   PubMed Web of Science ®Google Scholar
• Beaulieu PL. Finger loop inhibitors of the hepatitis C virus NS5B polymerase: discovery and prospects for new HCV therapy. Curr Opin Drug Discov Devel 2006;9:618-26
   PubMedGoogle Scholar
• Hirashima S, Suzuki T, Ishida T, et al. Benzimidazole derivatives bearing substituted biphenyls as hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitors: structure-activity relationship studies and identification of a potent and highly selective inhibitor JTK-109. J Med Chem 2006;49:4721-36
   PubMed Web of Science ®Google Scholar
• Beaulieu PL, Bös M, Bousquet Y, et al. Non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase: discovery of benzimidazole 5-carboxylic amide derivatives with low nanomolar potency. Bioorg Med Chem Lett 2004;14:967-71
   PubMed Web of Science ®Google Scholar
• Beaulieu PL, Bousquet Y, Gauthier J, et al. Benzimidazole-based allosteric inhibitors of the hepatitis C virus NS5B polymerase: inhibition of subgenomic hepatitis C virus RNA replicons in Huh-7 cells. J Med Chem 2004;47:6884-92
   PubMed Web of Science ®Google Scholar
• Beaulieu PL, Gillard J, Bykowski D, et al. Improved replicon cellular activity of non-nucleoside allosteric inhibitors of HCV NS5B polymerase: from benzimidazole to indole scaffolds. Bioorg Med Chem Lett 2006;16:4987-93
   PubMed Web of Science ®Google Scholar
• Genelabs Technologies Inc. WO08008907; 2008
   Google Scholar
• Genelabs Technologies Inc. WO08008912; 2008
   Google Scholar
• Boehringer-Ingelheim International GmbH. WO05080388; 2005
   Google Scholar
• Boehringer-Ingelheim International GmbH. WO06007693; 2006
   Google Scholar
• Erhardt A, Wedemeyer H, Benhamou Y, et al. Presented at the 42nd Meeting of the European Association for the Study of the Liver, Barcelona, Spain, April 11 – 15, Antiviral Res 2007; Manuscript in press
   Google Scholar
• Bechtell J. In vitro antiviral activity and resistance profile of GL60667 (NVP-LDI133), a potent non-nucleoside inhibitor of HCV NS5B polymerase. Presented at the 3rd International Resistance Workshop on Hepatitis C, Resistance and New Compounds. Boston, Mass. June 6 2008
   Google Scholar
• Genelabs Technologies Inc. WO06076529; 2006
   Google Scholar
• Ikegashira K, Oka T, Hirashima S, et al. Discovery of conformationally constrained tetracyclic compounds as potent hepatitis C virus NS5B RNA polymerase inhibitors. J Med Chem 2006;49:6950-3
   PubMed Web of Science ®Google Scholar
• Japan Tobacco Inc. WO05080399; 2005
   Google Scholar
• Japan Tobacco Inc. WO06052013; 2006
   Google Scholar
• Bristol-Myers Squibb Co. WO06020082; 2006
   Google Scholar
• Bristol-Myers Squibb Co. WO07033175; 2007
   Google Scholar
• Bristol-Myers Squibb Co. WO07092000; 2007
   Google Scholar
• Istituto Di Richerche Di Biologica Moleculare P Angeletti SpA. WO06046030; 2006
   Google Scholar
• Istituto Di Richerche Di Biologica Moleculare P Angeletti SpA. WO07029029; 2007
   Google Scholar
• Istituto Di Richerche Di Biologica Moleculare P Angeletti SpA. WO07054741; 2007
   Google Scholar
• Istituto Di Richerche Di Biologica Moleculare P Angeletti SpA. WO06119975; 2006
   Google Scholar
• Istituto Di Richerche Di Biologica Moleculare P Angeletti SpA. WO07129119; 2007
   Google Scholar
• Bristol-Myers Squibb Co. WO07033032; 2007
   Google Scholar
• Bristol-Myers Squibb Co. WO07136982; 2007
   Google Scholar
• Bristol-Myers Squibb Co. WO07140109; 2007
   Google Scholar
• Bristol-Myers Squibb Co. WO07140200; 2007
   Google Scholar
• Bristol-Myers Squibb Co. WO07140254; 2007
   Google Scholar
• Bristol-Myers Squibb Co. WO07143521; 2007
   Google Scholar
• Genelabs Technologies Inc. WO08011521; 2008
   Google Scholar
• Istituto Di Richerche Di Biologica Moleculare P Angeletti SpA. WO08075103; 2008
   Google Scholar
• De Francesco R, Paonessa G, Olsen D, et al. Robust antiviral efficacy of a “finger-loop” allosteric inhibitor of the hCV polymerase in HCV infected chimpanzees [abstract 24]. Presented at Hep DART 2007; December 9 – 13 2007; Lahaina, Hawaii
   Google Scholar
• NCT00635804: Study to evaluate the safety, tolerability and pharmacokinetics of MK-3281 in healthy and hepatitis C infected male patients. National Institute of Health, Bethesda, MD, USA; 2008. Available from: http://clinicaltrials.gov/show/NTC00635804
   Google Scholar
• Agouron Pharmaceuticals Inc. EP1256628; 2002
   Google Scholar
• Wang M, Ng KKS, Cherney MM, et al. Non-nucleoside analogue inhibitors bind to an allosteric site on HCV NS5B polymerase. J Biol Chem 2003;278:9489-95
   PubMed Web of Science ®Google Scholar
• Biswal BK, Cherney MM, Wang M, et al. Crystal structures of the RNA-dependent RNA polymerase genotype 2a of hepatitis C virus reveal two conformations and suggest mechanisms of inhibition by non-nucleoside inhibitors. J Biol Chem 2005;280:18202-10
   PubMed Web of Science ®Google Scholar
• Biswal BK, Wang M, Cherney MM, et al. Non-nucleoside inhibiors binding to hepatitis C virus NS5B polymerase reveal a novel mechanism of inhibition. J Mol Biol 2006;361:33-45
   PubMed Web of Science ®Google Scholar
• Chan L, Pereira O, Reddy TJ, et al. Discovery of thiophene-2-carboxylic acids as potent inhibitors of HCV NS5B polymerase and HCV subgenomic RNA replication. Part 2: tertiary amides. Bioorg Med Chem Lett 2004;14:797-800
   PubMed Web of Science ®Google Scholar
• Shire Biochem Inc. WO02100851; 2002
   Google Scholar
• Smithkline Beecham Corp. WO07039146; 2007
   Google Scholar
• Smithkline Beecham Corp. WO07071434; 2007
   Google Scholar
• Smithkline Beecham Corp. WO07088148; 2007
   Google Scholar
• Smithkline Beecham Corp. WO07147794; 2007
   Google Scholar
• Boehringer-Ingelheim International GmbH. WO07087717; 2007
   Google Scholar
• Boehringer-Ingelheim International GmbH. WO08019477; 2008
   Google Scholar
• NCT00389298: A proof-of-concept study of VCH-759 for the treatment of hepatitis C infection. National Institute of Health, Bethesda, MD, USA; 2006. Available from: http://clinicaltrials.gov/show/NTC00389298
   Google Scholar
• Cooper C, Lawitz EJ, Ghali P, et al. Antiviral activity of the non-nucleoside polymerase inhibitor, VCH-759, in chronic Hepatitis C patients: Results from a randomized, double-blind, placebo-controlled, ascending multiple dose study [abstract LB11]. 58th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, MA, November 2 – 6, 2007
   Google Scholar
• NCT00623649: Safety, tolerability and pharmacokinetics of multiple ascending doses of VCH-916 in subjects with chronic hep C infection. National Institute of Health, Bethesda, MD, USA; 2008.Available from: http://clinicaltrials.gov/show/NTC00623649
   Google Scholar
• Chauret N, Chagnon-Labelle C, Diallo M, et al. Preclinical pharmacokinetic and ADME characterization of VCH-916, a novel non-nucleoside HCV NS5B polymerase inhibitor. 43rd Annual Meeting of the European Association for the Study of the Liver, Milan, Italy, April 23 – 27, 2008
   Google Scholar
• Proulx L, Bourgault B, Chauret N, et al. Results of a safety, tolerability and pharmacokinetic phase I study of VCH-916, a novel polymerase inhibitor for HCV, following single ascending doses in healthy volunteers. 43rd Annual Meeting of the European Association for the Study of the Liver, Milan, Italy, April 23 – 27, 2008
   Google Scholar
• Howe AYM, Bloom J, Baldick CJ, et al. Novel nonnucleoside inhibitor of hepatitis C virus RNA-dependent RNA polymerase. Antimicrob Agents Chemother 2004;48:4813-21
   PubMed Web of Science ®Google Scholar
• Howe AYM, Cheng H, Thompson I, et al. Molecular mechanism of a thumb domain hepatitis C virus nonnucleoside RNA-dependent RNA polymerase inhibitor. Antimicrob Agents Chemother 2006;50:4103-13
   PubMed Web of Science ®Google Scholar
• Li H, Linton A, Tatlock J, et al. Allosteric inhibitors of hepatitis C polymerase: discovery of potent and orally bioavailable carbon-linked dihydropyranones. J Med Chem 2007;50:3969-72
   PubMed Web of Science ®Google Scholar
• Li H. Novel carbon-linked dihydropyrones as allosteric inhibitors of HCV RNA-dependent RNA polymerase. Presented at the Cambridge Healthtech Institute Drug Discovery Chemistry conference, San Diego, CA, April 28 – 30, 2008
   Google Scholar
• NCT00651027: Study to assess the impact of hepatic impairment on the safety, tolerability and pharmacokinetics of single-dose 200 mg of PF-868554. National Institute of Health, Bethesda, MD, USA; 2008. Available from: http://clinicaltrials.gov/show/NTC00651027
   Google Scholar
• NCT00671671: Phase 1 study to evaluate antiviral activity of small molecule direct antiviral agent at multiple doses in subjects with chronically infected hepatitis C virus. National Institute of Health, Bethesda, MD, USA; 2008. Available from: http://clinicaltrials.gov/show/NTC00671671
   Google Scholar
• Tedesco R, Shaw AN, Bambal R, et al. 3-(1,1-Dioxo-2H-(1,2,4)-benzothiadiazin-3-yl)-4-hydroxy-2(1H)-quinolinones, potent inhibitors of hepatitis C virus RNA-dependent RNA polymerase. J Med Chem 2006;49:971-83
   PubMed Web of Science ®Google Scholar
• Le Pogam S, Kang H, Harris ST, et al. Selection and characterization of replicon variants dually resistant to thumb- and palm-binding nonnucleoside polymerase inhibitors of the hepatitis C virus. J Virol 2006;80:6146-54
   PubMed Web of Science ®Google Scholar
• Molla A, Wagner R, Lu L, et al. Characterization of pharmacokinetic/pharmacodynamic parameters for the novel HCV polymerase inhibitor A-848837. J Hepatol 2007;46(Suppl 1):S234-5
   Google Scholar
• Hutchinson DK. Benzothiadiazine hepatitis C NS5B polymerase inhibitors. Presented at the Cambridge Healthtech Institute Drug Discovery Chemistry conference, San Diego, CA, April 28 – 30, 2008
   Google Scholar
• Bosse TD, Larson DP, Wagner R, et al. Synthesis and SAR of novel 1,1-dialkyl-2(1H)-naphthalenones as potent HCV polymerase inhibitors. Bioorg Med Chem Lett 2008;18:568-70
   PubMed Web of Science ®Google Scholar
• Abbott Laboratories. WO06093801; 2006
   Google Scholar
• Chen CM, He Y, Lu L, et al. Activity of a potent hepatitis C virus polymerase inhibitor in the chimpanzee model. Antimicrob Agents Chemother 2007;51:4290-6
   PubMed Web of Science ®Google Scholar
• Lu L, Dekhtyar T, Masse S, et al. Identification and characteriation of mutations conferring resistance to an HCV RNA-dependent RNA polymerase inhibitor in vitro. Antivir Res 2007;76:93-7
   PubMed Web of Science ®Google Scholar
• NCT00696904: Study of ABT-333 in both healthy volunteers and hepatitis C virus genotype 1 infected subjects. National Institute of Health, Bethesda, MD, USA; 2008. Available from: http://clinicaltrials.gov/show/NTC00696904
   Google Scholar
• Abbott Laboratories. WO08011337; 2008
   Google Scholar
• Donner PL, Xie Q, Pratt JK, et al. Des-A-ring benzothiadiazines: inhibitors of HCV genotype 1 NS5B RNA-dependent RNA polymerase. Bioorg Med Chem Lett 2008;18:2735-8
   PubMed Web of Science ®Google Scholar
• Hoffmann-La Roche Ag. WO07093541; 2007
   Google Scholar
• Anadys Pharmaceutical Inc. WO06066079; 2006
   Google Scholar
• Sergeeva MV, Zhou Y, Bartkowski DM, et al. Novel HCV NS5B polymerase inhibitors derived from 4-(1′',1′-dioxo-1′,4′-dihydro-1′l6-benzo[1′,2′,4′]thiadiazin-3′-yl)-5-hydroxy-2H-pyridazin-3-ones: Part 4. Optimization of DMPK properties. Bioorg Med Chem Lett 2008;18:3421-6 and references cited therein
   PubMed Web of Science ®Google Scholar
• Anadys Pharmaceutical Inc. WO07150001; 2007
   Google Scholar
• Anadys Pharmaceutical Inc. WO08051637; 2008
   Google Scholar
• Anadys Pharmaceutical Inc. WO08073982; 2008
   Google Scholar
• Anadys Pharmaceutical Inc. WO08082725; 2008
   Google Scholar
• Anadys Pharmaceutical Inc. WO08073987; 2008
   Google Scholar
• Anadys Pharmaceuticals Inc. News Release October 23rd2008. Available from: http//www.anadyspharma.com
   Google Scholar
• Slater MJ, Amphlett EM, Andrews DM, et al. Optimization of novel acyl pyrrolidine inhibitors of hepatitis C virus RNA-dependent RNA polymerase leading to a development candidate. J Med Chem 2007;50:897-900
   PubMed Web of Science ®Google Scholar
• Jarvest R. Design and Optimization of acylpyrrolidine inhibitors of HCV polymerase. Presented at the Cambridge Healthtech Institute Drug Discovery Chemistry conference, San Diego, CA, April 28 – 30, 2008
   Google Scholar
• NCT00439959: A double-blind, parallel, randomized, placebo-controlled, single and repeat dose escalation study to investigate the safety, tolerability and pharmacokinetics of GSK625433 in healthy subjects and in subjects who are chronically infected with hepatitis C. National Institute of Health, Bethesda, MD, USA; 2008. Available from: http://clinicaltrials.gov/show/NTC00651027
   Google Scholar
• Bright H, Bentley K, Carroll T, et al. Selection and characterization of HCV mutants resistant to an R200-hinge site inhibitor of NS5B polymerase. Presented at the 13th International Meeting on Hepatitis C Virus and Related Viruses, Cairns, Australia, August 27 – 31, 2006
   Google Scholar
• Howe AYM, Chunduru SK, Young DC, et al. Preclinical characterization of the non-nucleoside polymerase inhibitor HCV-796. Presented at the 13th International Meeting on Hepatitis C Virus and Related Viruses, Cairns, Australia, 27 – 31, August 2006
   Google Scholar
• Howe AYM, Cheng H, Johann S, et al. Molecular mechanism of hepatitis C virus replicon variants with reduced susceptibility to a benzofuran inhibitor, HCV-796. Antimicrob Agents Chemother 2008;52:3327-38
   PubMed Web of Science ®Google Scholar
• Chandra P, Raible D, Harper D, et al. Antiviral activity of the non-nucleoside polymerase inhibitor, HCV-796, in patients with chronic hepatitis C virus: preliminary results from a randomized, double-blind, placebo-controlled, ascending multiple dose study. Gastroenterology 2006;130(Suppl 2):A748
   Google Scholar
• Villano SA, Howe AD, Raible D, et al. Analysis of HCV NS5B variants following monotherapy with HCV-796, a non-nucleoside polymerase inhibitor, in treatment naïve HCV infected patients. Hepatology 2006;44(Suppl 1):607A
   Web of Science ®Google Scholar
• Villano SA, Raible D, Harper D, et al. Antiviral activity of the non-nucleoside polymerase inhibitor, HCV-796, in combination with pegylated interferon-2b in treatment-naïve patients with chronic HCV. J Hepatol 2007;46(Suppl 1):S24
   Web of Science ®Google Scholar
• ViroPharma Press Release, August 10th, 2007
   Google Scholar